Publications

Abstracts:

1. Thomas M, Jankovic J.      Dentatorubropallidoluysian Atrophy in North American Families Ann Neurol      2001; 50 (3) Suppl 1: S 65. 
2. Ondo      WG, Tintner R, Kwak C, Thomas M,      Jankovic J. Tetrabenazine for Huntington's disease Chorea: A single blind      study. Neurology 2001; 56 (suppl 3): A22. 
3. Thomas M, Jankovic J. Long term prognosis of Patients with      Psychogenic Movement Disorders. Neurology 2002; 58 Suppl 3: A483.
4. Thomas M, Jankovic J. Clinical      Heterogeneity of Pantothenate Kinase Associated Neurodegeneration (PKAN).      Neurology 2002; 58 Suppl 3: A 322. 
5. Protas      EJ, Thomas M, Cunha IT,      Caroline KS, Wankadia S, Jankovic J. Reliability of limits of stability measures in Parkinson's disease. Mov Disord 2002; 17 Suppl 5: S 128. 
6. Thomas M, Jankovic J,      Suteerawattanon M, Wankadia S, Caroline KS, Protas EJ. Gait and Balance      Scale: Validation and utilization. Mov Disord 2002; 17 Suppl 5: S 235. 
7. Protas EJ, Thomas M, Caroline K, Wankadia S,      Cunha IT, Jankovic J. Limits of stability in persons with Parkinson’s      disease. Combined Sections Meeting,      Tampa, FL, Feb. 15, 2003
8. Kavitha SC, Cunha I, Wankadia      S, Thomas M, Jankovic J, Protas      EJ. Correlation between balance and      gait in individuals with Parkinson’s disease. VA RR & D, Arlington, VA,      Febe 10-12, 2002
9. Thomas      M, Wankadia      S, Suteerawattananon M, Nguyen-Vuong K, Almaguer M, Protas E, Jankovic J.      Clinical gait and balance scale (GABS) in Parkinson’s disease: Development      and validation. Amer Acad Neurology, 2002
10. Thomas M, Ashizawa T, Jankovic J.      Minocycline in Huntington's disease : A pilot study. Mov Disord 2002; 17      suppl 5: S 237. 
11. Ondo      W, Wang A, Thomas M, Vuong KD.      Assessing factors which can influence spirograph performances in patients      with essential tremor. Mov Disord 2002; 17 suppl 5: S 344. 
12. Thomas M, Kim F. Underlying      Psychiatric Conditions in patients with Psychogenic Movement Disorders:      Recognition and Effective treatment. Abstract for Psychogenic Movement      Disorders Congress, Atlanta,       GA. Oct 2003. 
13. Levy      J, Thomas M. Biofeedback      therapy for Psychogenic Movement Disorders. Abstract for Psychogenic      Movement Disorders Congress, Atlanta,       GA. Oct 2003.
14. Thomas M, Jankovic J. Psychogenic      tremor: Characterization and Longitudinal Follow up. Abstract for Psychogenic      Movement Disorders Congress, Atlanta, GA. Oct      2003.
15. Thomas M, Jankovic J. Long term      follow up of patients with Psychogenic Movement Disorders. Abstract for      Psychogenic Movement Disorders Congress, Atlanta, GA.     Oct 2003.
16. Dimitrova      T, Bara-Jiminez W, Thomas M,      Bibbiani F, Zhiang X, Chase TN Continuous Dopaminergic Stimulation With Lisuride TTS (Patch) in Moderately Advanced Parkinsonian Patients Neurology 2003; S23.004, A185
17. Thomas M, Ashizawa T, Jankovic J.      Minocycline in Huntington’s disease: A pilot study, Abstract at the American Society of      Experimental Neurotherapeutics annual      meeting in April 2004. 
18. Jankovic      J, Vuong KD, Thomas M. Psychogenic      tremor: Characterization and longitudinal follow up. Abstract at American Academy of Neurology, 2004. 
19. Thomas M, Jankovic J. Long term      follow up of patients with Psychogenic Movement Disorders. Abstract at the      8th International Movement Disoders Congress, Rome, Italy,      June 2004. 
20. Thomas M, Vuong KD, Jankovic J.      Psychogenic dystonia: Clinical characteristics and long-term progression.      Mov Disord 2004;19(Suppl 9):S111. 
21. Azher      SN, Hernandez E, Goodman JC, Thomas      M. Biballism in Systemic Lupus Erythematosus and      Antiphospholipid Syndrome, Abstract at the 9th Movement      Disorders Congress, New Orleans, March 2005.
22. Dimitrova T, Bara-Jiminez W, Thomas M, Bibbiani F, Zhiang X,      Chase  T Continuous dopaminergic stimulation with lisuride TTS      (patch) in moderately advanced Parkinsonian patients S23.004,      A185 AAN 2006.
23. Thomas      M.     Study of Urokinase receptor in cerebrospinal fluid in Parkinson’s disease.      10 th International Congress of Parkinson’s disease and Movement Disorders,      Kyoto, Japan, October 2006. 
24. Thomas      M.     Soluble TNF alpha receptors in cerebrospinal fluid in patients with      Parkinson’s disease. 10 th      International Congress of Parkinson’s disease and Movement Disorders, Kyoto, Japan,      October 2006. 
25. Dominion Study Group:      Dopaminergic Therapy and Impulse Control disorders in Parkinsons disease: A cross sectional study.      International Congress of Parkinson’s disease and Movement Disorders, Chicago, USA, June 2008. 
26. Thomas      M.     Mutations in Parkinsons disease, Parkin and PINK1 , 12th     International Congress of Parkinson’s disease and Movement Disorders,      Chicago, USA, June 2008. 
27. Thomas      M.     Efficacy of Interleaving Electrode Programming in Deep Brain Stimulation      of Subthalamic nucleus in Parkinsons disease. International Congress of      Parkinsons disease AND Movement Disorders, Toronto, Canada, June 2011.
28. Adams, C., Fulbright, R., Thomas, M.; Cognitive dysfunction      in early Parkinson's disease: Neuropsychological analysis. Movement      Disorders 2012;27 Suppl 1 :29
29. Jankovic, J.J., Thomas, M., Vasquez, A., Sethi, K., Verma,      A., Pappert, E.J., et al; XCiDaBLE: A phase 4, observational, prospective      trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm      in the United States Preliminary baseline results on the health impact of      CD on patients using the cervical dystonia impact profile. Movement      Disorders 2012;27 Suppl 1 :1039. 

Original Articles: 

1. Thomas M, Jankovic J. Hallervorden Spatz Syndrome: Neurobase Grand Rounds 2001 (available online at www.medlink.comSept 2001).

2. Thomas M Stiff Person Syndrome: Case of the month. Online publication (available online at www.bcm.tmc.edu 1999. 

3. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine Treatment for Huntington's Disease-Associated Chorea. Clin Neuropharmacol 

2002;25(6):300-302. 

4. Thomas M, Hayflick SJ, Jankovic J. Clinical Heterogeneity of 

Neurodegeneration with Brain Iron Accumulation [Hallervorden Spatz 

Syndrome] and Pantothenate Kinase Associated Neurodegeneration [PKAN]. 

Movement Disorders Journal 2004; 19(1): 36-42.

5. Thomas M, Suteerawattanon M, Caroline KS, Wankadia S, Vuong KD, Protas EJ, Jankovic J. Gait and Balance Scale: Validation and Utilization. 

Journal of Neurological Sciences 2004; 217:89-99. 

6. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's Disease: A pilot study. Mov Disord 2004;19: 692-695.

7. Harris Brodsky, Kevin Dat Vuong, Thomas M, and Joseph Jankovic

Glabellar and palmomental reflexes in parkinsonian disorders Neurology 2004;  63: 1096-1098.

8. Ondo WG, Wang A, Thomas M, Vuong KD.  Evaluating factors that can influence spirography ratings in patients with essential tremor. Parkinsonism & Related Disorders, Volume 11, Issue 1, January 2005, Pages 45-48. 

9. Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome.CNS Spectr. 2006 Jul;11(7):501-8. 

10. Thomas M, Dat Vuong K, Jankovic J.      Long-term prognosis of patients with psychogenic movement disorders.:      Parkinsonism Relat Disord. 2006 12:382-387.

11. Eggenberger      ER, Lee AG, Thomas M, Lai EC.      Neuro-Opthalmologic findings in patients with Anti –GAD antibody syndrome.      Neuro-Opthalmology 2006; 30: 1-6.

12. At      risk for Huntington     disease: The PHAROS (Prospective Huntington At Risk Observational Study)      cohort enrolled. Huntington Study      Group PHAROS Investigators [Participating Investigator and author] Arch      Neurol. 2006 ;63:991-6.

13. Marder      K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study      Group [Participating investigator and author]. Dietary intake in adults at      risk for Huntington     disease: analysis of PHAROS research participants. Neurology. 2009 ;73: 385-92.

14. Daniel Weintraub, MD; Juergen Koester,      PhD; Marc N. Potenza, MD, PhD and DOMINION Study Group.Impulse      Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090      Patients [Participating investigator and author]. Arch Neurol  2010;67: 589-95.

Review Articles: 

1. Thomas M, Le WD, Jankovic J. Tetracycline derivatives: A novel 

therapeutic strategy in Neurodegenerative disorders ; Clin Neuropharm; 

2003; 26(1):18-23. 

2. Thomas M, Le WD. Minocycline in Parkinson’s Disease. Review article Current Pharmaceutical Design 2004; 10: 679-686 

3. Thomas M, Jankovic J. Psychogenic movement disorders: Diagnosis and management. CNS Drugs 2004; 18:437-52.

4. Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain.

Curr Opin Neurol. 2004; 17:437-442. 

Book Chapters:

1. Thomas M, Jankovic J. Botulinum      toxin in tics, stiff person syndrome, myoclonus, rigidity and Freezing. In      Handbook of Botulinum toxin treatment; Moore P and Lees A (Ed) Blackwell      Science Publications 2001. 
2. Thomas M, Jankovic J. Parkinson-plus      syndromes. In: Noseworthy J, ed. Neurologic Therapeutics: Principles and Practice, Martin Dunitz Ltd, London, UK  2001.
3. Thomas M, Jankovic J.      Neuroacanthocytosis. In: Noseworthy J, ed. Neurologic Therapeutics: Principles and Practice, Martin Dunitz Ltd, London, UK  2001.
4. Thomas M, Jankovic J. Clinical      diagnosis of vascular parkinsonism andnon- degenerative atypical parkinsonian      syndromes. Irene Litvan ed. Atypical Parkinsonian Syndromes. Humana Press      Inc, USA,      2004. 
5. Jankovic J, Thomas M. Psychogenic Tremor and Shaking. In: Hallett M,   Fahn S, Jankovic J, Lang AE, Cloninger CR, Yudofsky S, eds. Psychogenic Movement Disorders: Psychobiology and Therapy of a Functional Disorder, Advances in Neurology, Lippincott Williams and Wilkins, Philadelphia, 2004. 
6. Thomas M. Neurodegeneration with Brain      Iron Accumulation.Jankovic J and Tolosa E Eds. Lippincott Williams and Wilkins, Philadelphia, 2005. 
7. Thomas M, Jankovic J.      Neuroacanthocytosis. In: Noseworthy J, editor-in-chief, Neurological Therapeutics:      Principles and Practice, 2nd Edition, Martin Dunitz LTD, London, UK,      2006.   
8. Thomas M, Jankovic J. Parkinson-plus syndromes. In: Noseworthy J, editor-in-chief, Neurological Therapeutics: Principles and Practice, 2nd Edition, Martin Dunitz LTD, London, UK, 2006. 
9.  Thomas M, Jankovic J. Clinical diagnosis of vascular parkinsonism and non-degenerative atypical parkinsonian disorders. In: Litvan I, editor. Atypical parkinsonism. Totowa (NJ): Humana Press; 2008. 
10. Thomas M, Jankovic J. Psychogenic movement disorders. In: Fahn S, Lang A, Schapira A, editors. Movement disorders 4. Elsevier; 2009.

Others, including letters: 

1. Thomas M, Jankovic J, Reply to Comments from Martinez-Martinez, 

J Neurol Sci. 2004; Vol 221/1-2 pp 127. 

2. Thomas M, Jankovic J. Reply to Comments from Bonnelli et al; 

Clin Neuropharmacol. 2003 ; 26(5):223-4; author reply 224.

3. Thomas M, Ashizawa T, Jankovic J. Reply: Huntington's disease and 

minocycline. Mov Disord. 2005 Apr;20(4):511.

Editorial Projects: 

1. Inflammation in Parkinsons disease: A clinical and Scientific overview. Springer Neurology Publishers. Publication date October 2014.